Modification of Prasugrel based on a biological assay + prasugrel / clopidogrel
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Coronary Syndrome
Conditions
Acute Coronary Syndrome
Trial Timeline
Mar 1, 2012 → May 1, 2016
NCT ID
NCT01538446About Modification of Prasugrel based on a biological assay + prasugrel / clopidogrel
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrel is a approved stage product being developed by Daiichi Sankyo for Acute Coronary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01538446. Target conditions include Acute Coronary Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01538446 | Approved | Completed |
Competing Products
20 competing products in Acute Coronary Syndrome